AXGN Axogen Inc.

Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration

Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration

ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses® celebration. For 2021, the Rose Parade will be held as a televised special in Pasadena, CA on New Year’s Day.

This year’s Donate Life Rose Parade Celebration will honor 21 donors from across the country who have given the life-changing gift of donated tissue. Donate Life will also recognize six transplant professionals, including a nerve repair surgeon, for making donation and transplantation possible throughout the pandemic. Donate Life will prepare a “Community of Life” floral sculpture tribute for the event that honors the donors and health care heroes.

“The need for tissue and organ donation does not diminish during a pandemic,” said Karen Zaderej, chairman, CEO, and president of Axogen. “We are proud to support Donate Life as they continue to inspire people to register as organ and tissue donors. Pursuing our mission to restore nerve function and quality of life to patients with nerve injuries would not be possible without the gift of donated tissue.”

Axogen works year-round to support organizations like Donate Life and encourage organ and tissue donation. Register today to become an organ, eye or tissue donor by visiting .

About Donate Life America

Donate Life America is a nonprofit organization leading its national partners and Donate Life State Teams to increase the number of donated organs, eyes and tissues available to save and heal lives through transplantation while developing a culture where donation is embraced as a fundamental human responsibility. 

DLA manages and promotes Donate Life℠, the national brand for the cause of donation; motivates the public to register as organ, eye and tissue donors; provides education about living donation; manages the National Donate Life Registry at ; and develops and executes effective multi-media campaigns to promote donation. 

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Contact:

Axogen, Inc.

Annette Ruzicka, Corporate Communications

Peter Mariani, Chief Financial Officer



EN
23/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Axogen Inc.

 PRESS RELEASE

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Jefferies Global Healthcare Conference (London)Participation: Fireside chat and 1x1 investor meetingsDate/Time: Fireside Chat Tuesday, November 18, 2025, 4:30 PM GMTWebcast Link:  Canaccord Genuity MedTech...

 PRESS RELEASE

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Axogen, Inc. Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a ...

 PRESS RELEASE

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October...

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the con...

 PRESS RELEASE

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences: Cantor Global Healthcare Conference (NYC)Participation: Fireside chat and 1x1 investor meetings Date/Time: Fireside Chat Wednesday, September 3, 2025, 3:20 PM ETWebcast Link: Wells Fargo Healthcare Confere...

 PRESS RELEASE

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft FDA PDUFA goal date extended by three months ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FD...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch